Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Unicycive Therapeutics Inc (NQ: UNCY ) 0.5100 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Unicycive Therapeutics Inc < Previous 1 2 Next > Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing September 20, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Sciences Virtual Investor Forum Agenda Announced for September 19th September 16, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Unicycive: The Company Developing Key Kidney Therapies February 17, 2023 Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. Via TheNewswire.com Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD September 06, 2023 Appointment adds decades of drug development experience from a seasoned executive From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series August 29, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update August 14, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) July 21, 2023 Via ACCESSWIRE 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) July 21, 2023 Via ACCESSWIRE Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference July 20, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology July 18, 2023 Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program June 29, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET June 16, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report® June 09, 2023 Via ACCESSWIRE Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update May 16, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress April 24, 2023 Data highlights the potential safety and reno-protective effect of UNI-494 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Full Year 2022 Financial Results and Provides Business Update March 31, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug March 08, 2023 Via Investor Brand Network The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury March 07, 2023 By Julian Richard, Benzinga Via TheNewswire.com Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb March 06, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers March 03, 2023 By Julian Richard, Benzinga Via TheNewswire.com Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings February 27, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea February 02, 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings January 23, 2023 Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023 January 05, 2023 Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock December 29, 2022 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb December 28, 2022 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom December 22, 2022 Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) December 09, 2022 Via ACCESSWIRE Unicycive to Participate in Upcoming Investor Conferences November 28, 2022 Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction From Unicycive Therapeutics, Inc. Via GlobeNewswire Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy November 21, 2022 From Unicycive Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
